De novo immunosuppression with sirolimus and tacrolimus in heart transplant recipients compared with cyclosporine and mycophenolate mofetil: A one-year follow-up analysis

Transplantation Proceedings

Volumn 37, Issue 5, 2005, Pages 2231-2239

  Zucker, M J ^a   Baran, D A ^b   Arroyo, L H ^b   Goldstein, D J ^b   Neacy, C ^b   Mele, L ^b   Weinberg, A D ^b   Prendergast, T W ^b   Ribner, H S ^b  

^a NEWARK BETH ISRAEL MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; ARTERY DISEASE; ARTICLE; BACTERIAL INFECTION; CLINICAL ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; GRAFT REJECTION; HEART GRAFT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RATE; KAPLAN MEIER METHOD; KIDNEY FUNCTION; LEUKOCYTE COUNT; LOW DRUG DOSE; MALE; MEDIASTINITIS; MYCOSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RECIPIENT; SURVIVAL RATE; THROMBOCYTE COUNT; TREATMENT OUTCOME; URINARY TRACT INFECTION; VIRUS INFECTION; WOUND INFECTION;

ADRENAL CORTEX HORMONES; CYCLOSPORINE; DIABETES MELLITUS; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYCOPHENOLIC ACID; POSTOPERATIVE COMPLICATIONS; SIROLIMUS; SURVIVAL ANALYSIS; TACROLIMUS; TIME FACTORS;

EID: 21844459476     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2005.03.086     Document Type: Article

References (43)

1. D.O. Taylor, L.B. Edwards, P.J. Mohacsi The registry of the International Society for Heart and Lung Transplantation twentieth official adult heart transplant report-2003 J Heart Lung Transplant 22 2003 616
2. G. Vassalli, A. Gallino, M. Weis Alloimmunity and nonimmunologic risk factors in cardiac allograft vasculopathy Eur Heart J 24 2003 1180
3. B.K. Julius, C.H. Attenhofer Jost, G. Sutsch Incidence, progression and functional significance of cardiac allograft vasculopathy after heart transplantation Transplantation 69 2000 847
4. M.M. El Kossi, A. Ibrahim, T.J. Lock Impact of cardiac transplantation on kidney function a single- center experience Transplant Proc 35 2003 1527
5. R. Zietse, A.H. Balk, M.A. vd Dorpel Time course of the decline in renal function in cyclosporine-treated heart transplant recipients Am J Nephrol 14 1994 1
6. A.M. de Mattos, A.J. Olyaei, W.M. Bennett Nephrotoxicity of immunosuppressive drugs long-term consequences and challenges for the future Am J Kidney Dis 35 2000 333
7. H.O. Ventura, F.S. Malik, M.R. Mehra Mechanisms of hypertension in cardiac transplantation and the role of cyclosporine Curr Opin Cardiol 12 1997 375
8. H.J. Eisen Hypertension in heart transplant recipients more than just cyclosporine J Am Coll Cardiol 41 2003 433
9. L.W. Miller Cardiovascular toxicities of immunosuppressive agents Am J Transplant 2 2002 807
10. B. Radovancevic, B. Vrtovec Sirolimus therapy in cardiac transplantation Transplant Proc 35 2003 S171
11. A. Beniaminovitz, S. Itescu, K. Lietz Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody N Engl J Med 342 2000 613
12. I.A. Agha, J. Rueda, A. Alvarez Short course induction immunosuppression with thymoglobulin for renal transplant recipients Transplantation 73 2002 473
13. S.N. Sehgal Rapamune (RAPA, rapamycin, sirolimus) mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression Clin Biochem 31 1998 335
14. S.N. Sehgal Sirolimus its discovery, biological properties, and mechanism of action Transplant Proc 35 2003 S7
15. R.S. Poston, M. Billingham, E.G. Hoyt Rapamycin reverses chronic graft vascular disease in a novel cardiac allograft model Circulation 100 1999 67
16. C. Schmid, U. Heemann, H. Azuma Rapamycin inhibits transplant vasculopathy in long-surviving rat heart allografts Transplantation 60 1995 729
17. D. Mancini, S. Pinney, D. Burkhoff Use of rapamycin slows progression of cardiac transplantation vasculopathy Circulation 108 2003 48
18. R. Shapiro, V.P. Scantlebury, M.L. Jordan A pilot trial of tacrolimus, sirolimus, and steroids in renal transplant recipients Transplant Proc 34 2002 1651
19. J. Lawen, T. Keough-Ryan, C. Clase Sirolimus and low-dose tacrolimus with antibody induction in kidney transplantation preliminary results of a pilot study Transplant Proc 33 2001 3223
20. M.E. Billingham, N.R. Cary, M.E. Hammond The International Society for Heart Transplantation A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection Heart Rejection Study Group J Heart Transplant 9 1990 587
21. Q. Abid, U.U. Nkere, A. Hasan Mediastinitis in heart and lung transplantation 15 years experience Ann Thorac Surg 75 2003 1565
22. M. Carrier, L.P. Perrault, M. Pellerin Sternal wound infection after heart transplantation incidence and results with aggressive surgical treatment Ann Thorac Surg 72 2001 719, 723
23. J.F. Valente, D. Hricik, K. Weigel Comparison of sirolimus vs. mycophenolate mofetil on surgical complications and wound healing in adult kidney transplantation Am J Transplant 3 2003 1128
24. C. Troppmann, J.L. Pierce, M.M. Gandhi Higher surgical wound complication rates with sirolimus immunosuppression after kidney transplantation a matched-pair pilot study Transplantation 76 2003 426
25. A.E. Dutly, A. Gaspert, I. Inci The influence of the rapamycin-derivate SDZ RAD on the healing of airway anastomoses Eur J Cardiothorac Surg 24 2003 154 158
26. M.B. King-Biggs, J.M. Dunitz, S.J. Park Airway anastomotic dehiscence associated with use of sirolimus immediately after lung transplantation Transplantation 75 2003 1437
27. A.S. Mathis Comment delayed wound healing with sirolimus after liver transplant Ann Pharmacother 37 2003 453
28. C.J. Watson, P.J. Friend, N.V. Jamieson Sirolimus a potent new immunosuppressant for liver transplantation Transplantation 67 1999 505
29. O. Pridohl, K. Heinemann, T. Hartwig Low-dose immunosuppression with FK 506 and sirolimus after liver transplantation 1-year results Transplantation Proc 33 2001 3229
30. R.S. Poston, S. Husain, D. Sorce LVAD bloodstream infections therapeutic rationale for transplantation after LVAD infection J Heart Lung Transplant 22 2003 914
31. P.N. Malani, D.B. Dyke, F.D. Pagani Nosocomial infections in left ventricular assist device recipients Clin Infect Dis 34 2002 1295
32. S.M. Gordon, S.K. Schmitt, M. Jacobs Nosocomial bloodstream infections in patients with implantable left ventricular assist devices Ann Thorac Surg 72 2001 725
33. P. Sinha, J.M. Chen, M. Flannery Infections during left ventricular assist device support do not affect posttransplant outcomes Circulation 102 2000 111194
34. M. Argenziano, K.A. Catanese, N. Moazami The influence of infection on survival and successful transplantation in patients with left ventricular assist devices J Heart Lung Transplant 16 1997 822
35. M. Senechal, P. LePrince, S. Tezenas du Montcel Bacterial mediastinitis after heart transplantation clinical presentation, risk factors and treatment J Heart Lung Transplant 23 2004 165
36. C.W. Barlow, M.R. Moon, G.R. Green Rabbit antithymocyte globulin versus OKT3 induction therapy after heart-lung and lung transplantation effect on survival, rejection, infection, and obliterative bronchiolitis Transpl Int 14 2001 234
37. M. Carrier, G.B. Pelletier, R. Cartier Induction of immunosuppression with rabbit antithymocyte globulin five-year experience in cardiac transplantation Can J Cardiol 9 1993 171
38. A. Zuckermann, D. Dunkler, E. Deviatko Long-term survival (>10 years) of patients >60 years with induction therapy after cardiac transplantation Eur J Cardiothorac Surg 24 2003 283 291
39. B.L. Kasiske, J.J. Snyder, D. Gilbertson Diabetes mellitus after kidney transplantation in the United States Am J Transplant 3 2003 178
40. M.R. First, D.A. Gerber, S. Hariharan Posttransplant diabetes mellitus in kidney allograft recipients incidence, risk factors, and management Transplantation 73 2002 379
41. D.A. Baran, J. Ashkar, I.D. Galin Tacrolimus and new onset diabetes mellitus the effect of steroid weaning Transplant Proc 34 2002 1711
42. P.Y. Benhamou, A. Penfornis Natural history, prognosis, and management of transplantation-induced diabetes mellitus Diabetes Metab 28 2002 166
43. M.R. Mehra, P.A. Uber, R.L. Scott Ethnic disparity in clinical outcome after heart transplantation is abrogated using tacrolimus and mycophenolate mofetil-based immunosuppression Transplantation 74 2002 1568